- Home
- PGEN vs OLN Comparison
PGEN vs OLN Comparison
Compare PGEN & OLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PGEN | OLN |
|---|---|---|
| Founded | 1998 | 1892 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.5B |
| IPO Year | 2013 | 1994 |
Fundamental Metrics
Financial Performance| Metric | PGEN | OLN |
|---|---|---|
| Price | $8.21 | $15.96 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 15 |
| Target Price | $13.65 | ★ $21.27 |
| AVG Volume (30 Days) | ★ 3.6M | 2.2M |
| Earning Date | 11-12-2026 | 10-26-2026 |
| Dividend Yield | N/A | ★ 5.16% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | $230,981,000.00 | ★ $6,780,800,000.00 |
| Revenue This Year | $2,365.68 | $2.80 |
| Revenue Next Year | $85.75 | $4.64 |
| P/E Ratio | $271.00 | ★ N/A |
| Revenue Growth | N/A | ★ 3.68 |
| 52 Week Low | $2.99 | $15.38 |
| 52 Week High | $8.27 | $30.46 |
Technical Indicators
Market Signals| Indicator | PGEN | OLN |
|---|---|---|
| Relative Strength Index (RSI) | 72.48 | 26.51 |
| Support Level | $6.41 | N/A |
| Resistance Level | N/A | $24.81 |
| Average True Range (ATR) | 0.45 | 0.49 |
| MACD | 0.09 | -0.09 |
| Stochastic Oscillator | 84.01 | 3.59 |
Price Performance
Historical ComparisonAbout PGEN Precigen Inc.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
About OLN Olin Corporation
Olin was founded in 1892 and has been publicly listed since 1917. The company has a unique dual identity compared with some of its chemical peers: it is the world's largest chlor-alkali producer by capacity, and it owns the Winchester brand, a leading US ammunition manufacturer. Olin has three reportable segments: chlor-alkali products and vinyls (CAPV or CAP), Epoxies, and Winchester, which represent around 55%, 20%, and 25% of sales, respectively.